Peddock Capital Advisors LLC held its position in Pfizer Inc. (NYSE:PFE) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 41,372 shares of the biopharmaceutical company’s stock at the close of the second quarter. Pfizer makes up about 0.7% of Peddock Capital Advisors LLC’s investment portfolio, making the stock its 24th largest position. Peddock Capital Advisors LLC’s holdings in Pfizer were worth $1,390,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the company. Fisher Asset Management LLC lifted its position in shares of Pfizer by 3.9% in the 2nd quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after buying an additional 1,275,832 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Pfizer by 6.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 33,274,658 shares of the biopharmaceutical company’s stock worth $1,117,696,000 after buying an additional 2,013,835 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Pfizer by 0.9% in the 2nd quarter. Legal & General Group Plc now owns 31,463,283 shares of the biopharmaceutical company’s stock worth $1,056,857,000 after buying an additional 292,839 shares during the last quarter. Macquarie Group Ltd. lifted its position in shares of Pfizer by 0.9% in the 1st quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock worth $844,431,000 after buying an additional 228,405 shares during the last quarter. Finally, Boston Partners lifted its position in shares of Pfizer by 7.3% in the 1st quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after buying an additional 1,649,801 shares during the last quarter. Institutional investors own 69.34% of the company’s stock.

A number of research analysts have recently issued reports on the stock. Deutsche Bank AG set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. BMO Capital Markets set a $37.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, October 10th. Barclays PLC set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, Jefferies Group LLC set a $38.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a report on Monday, October 16th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the stock. Pfizer presently has an average rating of “Buy” and an average target price of $38.66.

Shares of Pfizer Inc. (NYSE:PFE) traded up $0.06 on Monday, hitting $35.49. 6,397,300 shares of the company’s stock traded hands, compared to its average volume of 20,093,064. Pfizer Inc. has a one year low of $30.51 and a one year high of $36.78. The firm has a market capitalization of $211,545.50, a PE ratio of 14.20, a price-to-earnings-growth ratio of 2.51 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same period last year, the company posted $0.61 earnings per share. The business’s revenue for the quarter was up .9% on a year-over-year basis. sell-side analysts forecast that Pfizer Inc. will post 2.6 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.61%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s payout ratio is 79.01%.

In related news, CEO Ian C. Read sold 197,168 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the completion of the sale, the chief executive officer now directly owns 580,318 shares in the company, valued at $19,730,812. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total transaction of $249,900.00. Following the sale, the insider now owns 132,124 shares of the company’s stock, valued at $4,492,216. The disclosure for this sale can be found here. Over the last quarter, insiders sold 366,557 shares of company stock valued at $12,532,406. Corporate insiders own 0.06% of the company’s stock.

WARNING: “Peddock Capital Advisors LLC Has $1,390,000 Holdings in Pfizer Inc. (PFE)” was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/peddock-capital-advisors-llc-has-1390000-holdings-in-pfizer-inc-pfe/1729263.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.